Skip to content
Study details
Enrolling now

MHBC Intervention Trial

Yale University
NCT IDNCT07224087ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

20

Study length

about 2 years

Ages

18–65

Locations

1 site in CT

What this study is about

This trial is testing a new treatment for weight loss and smoking cessation in people getting bariatric surgery. The treatment includes medication (Naltrexone + Bupropion) and behavior therapy, and it lasts 729 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Participate in Cognitive-Behavioral Therapy
  • 2.Take Bupropion HCl Extended Release
  • 3.Take Naltrexone Hydrochloride

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

bupropion, Antidotes, Deterrents, and Toxicologic Agents (Opioid Antagonists)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Percent weight change

Secondary: Depressive symptomatology, as measured by the Patient Health Questionnaire-9

Procedures

therapy

Body systems

Endocrinology